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Objective:To evaluate the psychometric properties of the Minnesota
Living with Heart Failure Questionnaire (MLHF-Q) in patients with atrial
ﬁbrillation. 
Design: A prospective study of the patients who underwent DC electrical
cardioversion.
Setting: Clinics of cardiology and thoracic surgery of the University Hospital in
Groningen, the Netherlands.
Main outcome measures: The disease-speciﬁc MLHF-Q and generic
measures of quality of life were administered. The sensitivity to change over
time was tested with effect sizes (ES). Internal consistency of MLHF-Q scales
was estimated with Cronbach’s alpha. To evaluate the construct validity
multitrait–multimethod analysis was applied. The ‘known group validity’ was
evaluated by the comparison of mean scores and effect sizes between two
groups of the New York Heart Association (NYHA) classiﬁcation (NYHA I
versus II–III). Stability of MLHF-Q scales was estimated in a subgroup of
patients who remained stable. Perfect congruence analysis and factor analysis
were applied to conﬁrm the a priori determined structure. 
Results: Cronbach’s alpha was ³0.80 of the MLHF-Q scales. Perfect
congruence analysis (PCA) showed that the results resemble quite well the
a priori assumed factor structure. Multitrait–multimethod analysis showed
convergent validity coefﬁcients ranging from 0.59 to 0.73 (physical impairment
dimension) and 0.39 to 0.69 (emotional dimension). The magnitude of change
can be interpreted as medium (ES = 0.50). The results of a ‘test–retest’
analysis in a stable group can be valued as satisfactory for the MLHF-Q
scales (Pearson’s r > 0.60). The physical dimension and the overall score of
the MLHF-Q discriminated signiﬁcantly between the NYHA I and II–III groups
(p < 0.001) with large effect sizes (ES > 1.0). 490 B Middel et al.
Introduction
In assessing health-related quality of life and
functional ability or health status, a distinction is
made between disease-speciﬁc outcome measures
developed to measure quality of life dimensions
characteristic for patients having a particular dis-
ease, and generic instruments measuring more
broadly deﬁned dimensions of quality of life.
Both types of instruments have their strengths
and weaknesses.1 An advantage of generic instru-
ments is that they have a broad scope and can be
used in many populations on a wide variety of
diseases. A disadvantage is that general aspects
of quality of life that are not signiﬁcant for a spe-
ciﬁc disease will result in a less valid assessment
of the concept of health-related quality of life in,
for example, groups of (chronic) disease. Assess-
ing only those aspects of quality of life which are
determined to be due to a particular disease will
result in a short instrument that will be more sen-
sitive to detect change in disease-speciﬁc groups
after (medical) interventions. A disadvantage of
a disease-speciﬁc instrument is that study results
are difﬁcult to compare with other populations.
In the current study, health-related quality of life
was assessed with the disease-speciﬁc Minnesota
Living with Heart Failure Questionnaire
(MLHF-Q), the generic RAND-36 or Short
Form (SF-36),2 the Multidimensional Fatigue
Inventory (MFI-20)3–5 and the Hospital Anxiety
and Depression Scale (HADS).6,7 The data were
appropriate to conduct a validation study to esti-
mate the sensitivity to change (responsiveness),
the reliability and validity of the disease-speciﬁc
MLHF-Q to obtain data for its future use in
(Dutch) clinical evaluation studies. 
The MLHF-Q consists of 21 items and
addresses a wide range of health-related quality
of life aspects.8 In this article the psychometric
properties of the Dutch version of the MLHF-Q
scales are evaluated and validated with concep-
tually similar dimensions of generic instruments,
the RAND-36, the HADS and the MFI-20. 
All instruments are self-report measures of
quality of life on the dimensions of physical,
mental or social well-being. The psychometric
properties of the MLHF questionnaire have been
evaluated previously in its English version and
the instrument has been used as an outcome
measure in clinical trials in the context of the
American health care system.9–14 In other coun-
tries there have been only a few studies on the
evaluation of the reliability and validity of the
MLHF-Q up till now.15,16 The RAND-36 was
chosen as the generic counterpart because it is a
generally accepted and well-validated instrument,
it is a short questionnaire with known psycho-
metric properties,17–20 it resembles closely the
MLHF-Q dimensions and it is available in a
Dutch version.21,22
The objectives of this study were:
• To compare the results from the MLHF-Q
with the RAND-36, HADS and MFI-20 in
terms of reliability and sensitivity to detect
change over time. It was hypothesized that
the MLHF-Q would demonstrate a compara-
ble magnitude of change over time.
• To compare the results of the questionnaire’s
clinical validity. It was hypothesized that the
MLHF-Q would demonstrate that the more
severely angina was rated by the New York
Heart Association (NYHA) classiﬁcation, the
greater the deterioration in the patient’s
quality of life. The change assessed in a
group of patients who remained clinically
unchanged or stable was hypothesized to be
due to chance ﬂuctuation.
• To ﬁnd support for the factor structure orig-
inally found by Rector and Cohn12 in our
data. 
• To provide empirical evidence that the
MLHF-Q scale measures the underlying con-
structs of physical and emotional impair-
ments it is reputed to represent.
The purpose of the present study was to use
the data of a treatment–outcome study to deter-
mine the performance of the MLHF-Q. The
results of the clinical efﬁcacy study will be pub-
lished elsewhere.
Conclusions: The MLHF-Q has solid psychometric properties and the out-
come of the current study indicates that the MLHF-Q is an effective and
efﬁcient instrument.Minnesota Living with Heart Failure Questionnaire 491
scale on change in perceived health was not used
in the transformation of scores into a scale
because the MLHF questionnaire does not con-
tain an item assessing change in perceived health.
The RAND-36 item scores are summed and
transformed to eight scales, each with scores
between 0 and 100, where 0 represents the
unhealthiest state and 100 the best health state
possible.2,22
The MLHF-Q is a disease-speciﬁc instrument
composed of 21 items and three scales that mea-
sure: the physical dimension (8 items), the emo-
tional dimension (5 items) and the overall score
on health-related quality of life (21 items). Eight
separate items, which do not assess a single con-
struct or dimension of health-related quality of
life, measure social and economical impairments
patients relate to their heart failure and are part
of the overall score.The total score has a range
between 0 and 105, the physical dimension (sub-
scale) between 0 and 40, the emotional dimen-
sion (subscale) between 0 and 25 and the
separate items on the socio-economic impair-
ments between 0 and 40.
High scores on the MLHF-Q scales indicate a
high negative impact of heart disease on the
assessed aspects of quality of life.
The Multidimensional Fatigue Inventory
(MFI-20) consists of 20 items and ﬁve subscales
(general, physical, activity, motivation and cogni-
tion). Each scale consists of four items and has a
range from 4 to 20 and its total score ranges from
20 to 100. High scores indicate high fatigue. The
subscales anxiety and depression of the Hospital
Anxiety and Depression Scale (HADS) have a
range between 0 and 21. A score of 7 or lower
identiﬁes ‘non cases’, 8 to 10 ‘doubtful cases’ and
a score ³11 ‘deﬁnite cases’. 
Quantitative analysis 
The features of the distribution of scores on
the conceptually similar dimensions of the
MLHF-Q, MFI-20, HADS and RAND-36 were
computed. Mean scores, standard deviations and
the percentage of patients with the maximum
possible score (ceiling) and the minimum possi-
ble score (ﬂoor) are represented. 
In the examination of the construct validity of
the MLHF-Q, scales of all instruments were used
in the analysis. It was hypothesized that the scales
Methods 
Consecutive patients scheduled for DC electrical
cardioversion were included in this study.
Patients presented with atrial ﬁbrillation and
atrial ﬂutter and were treated at the department
of cardiology and thoracic surgery of the Uni-
versity Hospital in Groningen.
Out of the 60 consecutive candidates for DC
electrical cardioversion screened for inclusion,
ﬁve patients died within 12 months after the
completion of the ﬁrst questionnaire. One year
after the ﬁrst visit to the clinic, 44 patients
out of 55 (80.0%) returned the questionnaire
used for analysis of reliability and validity of the
MLHF-Q. 
All patients completed the questionnaires as a
baseline assessment before the ﬁrst treatment
(DC electrical cardioversion) in the department
of cardiology and thoracic surgery of the Uni-
versity Hospital Groningen. The patients were
invited to participate in the study by the cardiol-
ogist and after informed consent the patients
completed the questionnaires, undisturbed, in a
separate room. The cardiologist was blinded to
the information of the questionnaires. The sec-
ond and third assessment was at home, three and
12 months after the ﬁrst electrical cardioversion
respectively. The questionnaires were returned in
a pre-paid envelope to the Northern Centre for
Healthcare Research of the University of
Groningen.
Measurements
Both demographic characteristics of the
patients and relevant medical background vari-
ables were administered with standard or usual
questions and items in the medical examination
procedure at the ﬁrst visit to the outpatient clinic.
To assess the impact of the treatment on daily
physical, emotional and social functioning four
instruments were used. The RAND-36 is a
generic instrument and consists of 36 items that
contribute to eight scales that measure the fol-
lowing aspects of health: ‘physical functioning’
(10 items), ‘social functioning’ (2), ‘role limita-
tions due to physical problems’ (4), ‘role limita-
tions due to emotional problems’ (3), ‘mental
health’ (5), ‘energy/vitality’ (4), ‘pain’ (2) and
‘general health perception’ (5). The one-item492 B Middel et al.
that are strongly conceptually associated would
show strong correlations and scales that are con-
ceptually associated more weakly would demon-
strate lower correlation coefﬁcients.
In this study the internal consistency of the
MLHF-Q, RAND-36, HADS and MFI-20 scales
was tested with Cronbach’s a23 to make compar-
isons between the instruments’ mean alphas. An
a coefﬁcient >0.80 was considered as sufﬁcient,24
irrespective of the number of items. Perfect con-
gruence analysis and factor analysis were applied
to conﬁrm the a priori determined structure on
which Rector and Cohn12 have selected the items. 
Test–retest stability of the MLHF-Q scales was
assessed with correlation coefﬁcients between
baseline and three months after cardioversion in
a group in which the treatment was not success-
ful (that showed no sinus rhythm three months
after the ﬁrst electrical cardioversion), so their
health status remained unchanged or stable.
Although the test–retest procedure was not car-
ried out by sending the questionnaire shortly
after the ﬁrst completion, we were interested in
the variability of the MLHF-Q scores between
two points in time within a group whose condi-
tion remained stable. However, high test–retest
correlation coefﬁcients as such do not give us
information about the changes in time between
baseline and three-month outcome scores and
therefore we tested the hypothesis that the
change over time in a stable group is due to
chance ﬂuctuations. The Wilcoxon matched-pairs
signed-rank test was used due to the non-normal
distribution of the outcome assessments.
To estimate the responsiveness, the ability of
an instrument to detect the magnitude of
change over time within one group, we used
Cohen’s effect size statistic d for paired observa-
tions.25 As the variance of the post-test measure
is partly explained by the pretest scores, estimat-
ing the magnitude of the change between base-
line and post-test in the treated group requires
adjustment of the effect size d' for the correla-
tion (r) between the baseline and post-test
scores26,27:
d' x –
baseline – x –
post-test
d = d' =
√ 1 – r SD (xbaseline xpost-test)
where d' is the effect size = mean change/pooled
SD baseline and post-test score; d is the effect
size adjusted for r; r is the correlation coefﬁcient
between repeated measurements.
An effect size of 0.20 has to be interpreted as
a small effect, an effect size of 0.50 a medium
effect and an effect size of >0.80 a large effect.25,28
To evaluate the ability of the MLHF-Q to dis-
criminate between subgroups of patients which
are known to differ on an accepted classiﬁcation
of the seriousness of the disease, the ‘known
groups validity’ of the MLHF-Q scales was
tested.29 The Mann–Whitney U Wilcoxon rank
sum test was used because of the non-normal dis-
tribution of the variables in the analysis. The
grouping condition was NYHA classiﬁcation I
versus II and III (due to the small number of
observations class II and III were combined).30
Cohen’s effect size d' for unrelated samples to
estimate the magnitude of the difference in mean
scores between these groups was calculated by
dividing the mean difference score by the pooled
standard deviation for groups with unequal num-
ber of observations31:
x –
NYHA I – x –
NYHA II-III
d' =
SD (xNYHA I xNYHA II-III)
Results
Table 1 shows the descriptive statistics of the
sample. The mean (range) age of the patients in
the study was 61.5 (range 28–87) years. A minor-
ity of the patients were female (35%). The major-
ity of the patients had one or more heart diseases
or other relevant diseases in addition to atrial ﬁb-
rillation (AF). Only six persons had AF without
any other disease. Almost half of the patients
(46.7%) had two or more diseases next to AF. A
relatively large group (41.7%) was treated for the
ﬁrst time for AF. The  mean score on the NYHA
classiﬁcation (range 1–4) of 1.9 indicates a mod-
erate severity of the underlying disease. 
Distribution of scores, internal consistency
and responsiveness
Mean baseline and post-test (1 year) scores,
standard deviations and the percentages ofMinnesota Living with Heart Failure Questionnaire 493
were below this level (0.79, 0.79 and 0.76 respec-
tively). The reliability coefﬁcients of the MLHF-
Q scales remained satisfactory one year after
enrolment.
The scales of the MLHF-Q at baseline assess-
ment yielded internal consistency estimates
(mean  a = 0.85; range = 0.82–0.88) equal to the
RAND-36 (mean a = 0.86; range = 0.79–0.93)
and somewhat higher than those of the HADS
(mean a = 0.83; range = 0.83–0.84) and MFI-20
(mean  a = 0.84; range = 0.76–0.88). The ability to
detect change over time within one group with
paired observations was estimated with the effect
size proposed by Cohen.25 An effect size of 0.20
has to be interpreted as a small effect, an effect
size of 0.50 a medium effect and an effect size of
>0.80 a large effect. Large effect sizes were not
found. The MLHF-Q scales showed medium
effect sizes. The RAND-36 scales ‘role limita-
tions due to emotional problems’ and ‘pain’
demonstrated small effect sizes and ‘general
health perception’ showed no ability to detect
change between baseline and one year outcome
assessment. The HADS-anxiety scale and the
MFI-20 general fatigue scale showed medium
effect sizes. The physical and emotional dimen-
sions of the RAND-36, HADS and MFI-20
demonstrate comparable indicators of change
over time within this particular group.
Item analysis
The MLHF-Q contains three dimensions or
scales: a physical dimension, an emotional dimen-
sion and a global quality of life dimension. A
comparison was made with the results of the fac-
tor analysis of Rector and Cohn.2 Their data pro-
vided us with an a priori assumed four-factor
structure that was forced in order to evaluate the
congruence of our data with the original struc-
ture. Therefore, a computer program for simul-
taneous component analysis (SCA) for variables
measured in two or more populations was
applied.32 The four a priori assumed factors
based on the structure in the data of Rector and
Cohn explained 58% of the total variance as a
result of the SCA-perfect congruence analysis
(PECON).33 A principal component analysis with
rotation according to the varimax criterion was
performed without the constraints of the struc-
ture elaborated by Rector and Cohn. In this
patients with the maximum and minimum scores,
are shown in Table 2. A study of the distribution
of scores of the MLHF-Q scales showed a skew-
ness in the direction of positive functioning or lit-
tle or no impairment. The RAND-36 data
showed the same tendency for four scales (social
functioning, emotional role functioning, pain and
health perception). The RAND-36 scale ‘physi-
cal role functioning’ showed a tendency towards
the opposite direction. Three conceptually
related scales of the MFI (‘physical’, ‘activity’ and
‘general’ feelings of fatigue) were skewed in the
direction of little impact on health-related qual-
ity of life, while the cognition scale was skewed
in the negative direction. The Cronbach’s alphas,
the internal consistency coefﬁcients, of the
MLHF-Q, RAND-36, HADS and MFI-20 scales
are also shown in Table 2. The internal consis-
tency of the MLHF-Q scales had a satisfactory
level of reliability (a > 0.80).24 Only the RAND-
36 scales ‘social functioning’ and ‘general
health perception’ and the MFI-scale ‘cognition’
Table 1 Patient characteristics at study enrolment
(n = 60)
No. (%)
Gender
Men 39 (65.0)
Women 21 (35.0)
Mean age (years) 61.5 (SD 12.7)
Marital status
Married/living with partner 39 (60.0)
Widowed/unmarried/divorced 16 (24.6)
Missing value 5 (15.4)
Disease
AVD 12 (20.0)
MVD 12 (20.0)
Hypertension 16 (26.7)
Congenital heart disease 7 (11.7)
Coronary artery disease 11 (18.3)
Cardiomyopathy 4 (6.7)
Hyperthyroidism 2 (3.3)
Chronic obstructive pulmonary disease 9 (15.0)
Miscellaneous 16 (26.7)
No disease 6 (10.0)
1 disease 26 (43.3)
2 diseases 21 (35.0)
3–4 diseases 7 (11.7)
Mean NYHA classiﬁcation 1.9 (SD 0.6)
AVD, aortic valve disease; MVD, mitral valve disease.494 B Middel et al.
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erogeneous set of health-related aspects of heart
failure. Factor 2 demonstrates high loadings of
the items on the physical dimension. Although all
the items of the emotional dimension had high
loadings on factor 1, the following items also
showed high loadings: ‘making going away from
home difﬁcult’ (physical dimension), ‘ankle
oedema’, ‘hospitalization’ and ‘medical costs’
(socio-economic impairments) on this factor.
Construct validity 
In this study we attempted to provide evidence
that the MLHF-Q scales measure the underlying
constructs of physical and emotional impairments
they are reputed to represent.
The multitrait–multimethod approach outlined
by Campbell and Fiske34 was used to assess the
convergent and divergent validity of the MLHF-
Q measures of physical and emotional impair-
ment. 
Convergent validity (i.e. evidence that we are
measuring what we purport to measure) is pro-
vided by data that show that different measures
of conceptually related dimensions of health-
analysis the four factors explained 61% of the
total variance. This difference of 3% indicates an
acceptable discrepancy, but still indicates an
insufﬁcient recognition in our data. A fourth
socio-economic dimension of impairments that
patients relate to their heart failure was sug-
gested by Rector et al.9 but in the current study
the items did not load on a socio-economic com-
ponent. As demonstrated by the matrix (Table
3), 6 out of the 21 items had very high loadings
(>0.70) and 13 items had high loadings
(>0.50–<0.70) on their respective factors. Only
one item had a high loading on two factors
(impairment because of ankle oedema). On face
value we may conclude that the results closely
resemble the ﬁndings of Rector and Cohn.12 A
closer inspection of the four-factor solution, how-
ever, shows some deviations from the original
factor structure: two items of the physical dimen-
sion identiﬁed by Rector and Cohn (‘making
sleeping well at night difﬁcult’ and ‘making your
relating to or doing things with your friends or
family difﬁcult’) have a high loading on factors 3
and 4, representing the impairments on a het-
Table 3 Principal components factor analysis with varimax rotation of the MLHF-Q
Factor 1 Factor 2 Factor 3 Factor 4
Making you stay in a hospital 0.69a 0.23 0.10 –0.13
Making you feel you are a burden to your family 0.62b 0.12 0.36 –0.34
Making you feel depressed 0.70b 0.06 0.33 0.26
Making you worry 0.69b 0.16 –0.05 0.14
Making you feel a loss of self-control in your life 0.64b 0.37 0.17 0.09
Making going away places away from home difﬁcult 0.67c 0.35 0.11 0.21
Making it difﬁcult for you to concentrate or remember
things 0.65b 0.01 0.01 0.33
Costing you money for medical care 0.47a 0.18 0.25 –0.29
Causing swelling your ankles, legs, etc. 0.52a 0.52 –0.01 –0.02
Making walking about or climbing stairs difﬁcult 0.26 0.83c 0.10 0.02
Making working around the house or yard difﬁcult 0.31 0.79c 0.26 0.19
Making you sit or lie down to rest during the day 0.40 0.73c 0.11 –0.01
Making you tired, fatigued or low on energy 0.27 0.54c 0.31 0.25
Making you short of breath –0.06 0.60c 0.31 0.26
Making sexual activities difﬁcult 0.02 0.13 0.82a 0.16
Making you eat less of the foods you like 0.06 –0.07 0.76a 0.16
Making recreational pastimes, sports or hobbies difﬁcult 0.13 0.49 0.68a 0.17
Making your relating to or doing things with your
friends or family difﬁcult 0.28 0.26 0.47c 0.24
Side effects from medications 0.22 0.32 0.56a –0.06
Making working to earn a living difﬁcult 0.11 0.10 0.21 0.73a
Making sleeping well at night difﬁcult 0.10 0.22 0.39 0.60c
aSingle items used in the construction of the overall score.
bEmotional dimension.
cPhysical dimension.496 B Middel et al.
To demonstrate divergent validity the multi-
trait–monomethod correlation coefﬁcients must
be higher than the correlation coefﬁcients for
variables that have neither trait nor method in
common. The values that represent relations
between the components of physical and emo-
tionally impaired quality of life, which are repre-
sented in the area enclosed by broken lines, are
of interest. Most of the scales that are supposed
to measure different constructs are weakly cor-
related, independent from the method that is
used. In accordance with our expectation, some
correlations were of moderate magnitude simply
due to shared method variance (printed in bold).
This analysis provides reassurance that with
the MLHF-Q we are measuring physical impair-
ment and that there is convergence among meth-
ods. The emotional impairment component,
however, is moderately associated with the other
methods.
Test–retest 
If a quality of life instrument like the MLHF-
Q is developed to be used as an evaluative instru-
ment in clinical trials, one of the conditions which
should be fulﬁlled is that it has the ability to
demonstrate stability over time in subjects
whose health status does not change (test–retest
reliability).36
Table 5 shows the test–retest correlation coef-
ﬁcients after a period of three months of stabil-
ity in health status without serious cardiac events.
related quality of life are highly correlated.35,36 In
addition, we expect that each of the measures of
physical and emotional dimensions of quality of
life measures a different construct (i.e. that the
‘physical fatigue’ scale does not measure depres-
sion (divergent validity).
In Table 4 multitrait–multimethod matrices
were constructed for each of the assessed dimen-
sions of quality of life (physical and emotional).
Evidence of convergent validity is drawn from
examination of the coefﬁcients in the hetero-
trait–heteromethod triangles, enclosed by solid
lines in Table 4. We also expect some association
between the scales measuring dimensions of,
for example, physical quality of life if the
same questionnaire (method) was used and
items were not presented in a randomized order
(correlated measurement error). These hetero-
trait–monomethod coefﬁcients are depicted in
bold. In the area enclosed by broken lines the
coefﬁcients between variables that have no trait
in common are shown.
The correlations between the three generic
methods and the MLHF-Q scale assessing physi-
cal impact on quality of life are, as expected, high
and have the same magnitude as the hetero-
trait–monomethod coefﬁcients. The correlations
between the three generic methods and the
MLHF-Q scale assessing emotional impact, while
statistically signiﬁcant, are moderate (except the
correlation between the HADS depression scale
with the RAND ‘role emotional’ scale).
Table 4 Multitrait–multimethod matrix for the emotional and mental dimensions of health-related quality of life (n = 60)
Constructs 1 2 3 4 5 6 7 8 9 10
1. MLHF physical dimension
2. RAND-36 physical functioning –0.65
3. RAND-36 role – physical –0.60 0.64
4. RAND-36 energy/vitality –0.73 0.66 0.61
5. MFI-20 physical 0.63 –0.72 –0.59 –0.70
6. MLHF emotional dimension 0.44 –0.28 –0.35 –0.34 0.37
7. RAND-36 mental health 0.32 0.35 0.31 0.53 –0.35 –0.46
8. RAND-36 role – emotional 0.33 0.27 0.49 0.43 –0.27 –0.47 0.50
9. HADS anxiety 0.30 –0.24 –0.30 –0.25 0.42 0.43 –0.60 –0.59
10. HADS depression 0.44 –0.46 –0.37 –0.46 0.35 0.44 –0.59 –0.39 0.55
All correlations p < 0.01; corresponding dimensions are printed bold.
The areas surrounded by solid lines are the heterotrait–heteromethod triangles.
The area surrounded by broken lines comprises the coefﬁcients for variables that have no trait in common (the
hetereotrait–monomethod coefﬁcients are depicted bold in both areas).Minnesota Living with Heart Failure Questionnaire 497
groups (p < 0.001) with large effect sizes. The
MLHF emotional dimension also discriminated
clearly between these groups (p = 0.01) but with
a moderate effect size. 
Discussion
To what extent does the Dutch version of the
MLHF-Q measure the desired underlying con-
cept or reﬂect what it is supposed to measure? In
this study, the MLHF-Q construct validity was
determined by higher and signiﬁcant correlation
coefﬁcients between the MLHF-Q scales and cor-
responding dimensions of the MFI-20, HADS
and the RAND-36 and by lower correlations with
noncorresponding dimensions of health-related
quality of life of these instruments. The MLHF-
Q ‘physical’ dimension showed higher correla-
tions with the RAND-36 scales ‘social
functioning’, ‘energy vitality’, ‘health perception’
and ‘pain’, indicating that these domains of qual-
ity of life, which are not tagged by the MLHF-Q,
are more likely to be associated with physical lim-
itations in this study group. 
One of the great advantages in clinical trials is
The results can be valued as satisfactory for all
MLHF-Q scales. However, although we can
interpret the test–retest correlation coefﬁcients as
satisfactory, these estimates of linear relation-
ships do not provide information about the exis-
tence of signiﬁcant change in a selected group
of stable patients. To test the statistical signiﬁ-
cance of the change between baseline and three-
month outcome the Wilcoxon matched-pairs
signed-rank test was used because of the non-
normal distribution of the MLHF-Q scales. None
of the MLHF-Q scales demonstrated signiﬁcant
change. 
Known group validity
To evaluate the ability of the MLHF-Q dimen-
sions to discriminate between so-called ‘known
groups’ who should differ based on the cardiolo-
gists’ (blinded) classiﬁcation of the severity of the
disease, the study sample was divided into two
subgroups: NYHA classiﬁcation I and II–III. The
results of the analysis of the ability of the MLHF-
Q scales to discriminate between ‘known groups’
are presented in Table 6. The physical dimension
and the overall score of the MLHF-Q discrimi-
nated sharply between the NYHA II–III and I
Table 5 Means, standard deviations (SD), test–retest correlations (r) and difference in scores between baseline and
three-month outcome in a group of patients that did not show improvement in sinus rhythm
Mean (t1) SD (t1) Mean (t2) SD (t2) r z-score p-value
MLHF-Q
Physical dimension (n = 19) 14.39 9.59 15.91 12.91 0.70 –0.23 0.82
Emotional dimension (n = 19) 6.05 5.77 4.63 4.69 0.63 –1.47 0.14
Overall score (n = 19) 29.79 18.65 26.00 20.34 0.73 –1.28 0.20
Table 6 Discriminative ability of the MLHF-Q between NYHA classiﬁcation groups
NYHA class I (n = 15) NYHA class II and III
(n = 38)
Rank suma
Dimension Mean SD Mean SD z-value p-value Effect sizeb
MLHF-Q
Physical dimension (0–40) 5.5 7.1 16.7 9.0 –3.8 0.0001 1.31
Emotional dimension (0–25) 3.5 6.4 6.5 5.3 –2.5 0.01 0.53
Overall score (0–105) 11.7 16.5 33.9 18.1 –3.6 0.0003 1.25
aMann–Whitney U, one-sided.
bEstimation of the effect size used Cohen’s d for independent samples when n1 ≠ n2, which is deﬁned as the difference
in mean scores divided by the pooled standard deviation: est. s = √(N1 – 1)s1
2 + (N2 – 1)s2
2 / (N1 –1) + (N2 –1).498 B Middel et al.
(effect size > 1) and statistically signiﬁcant (p <
0.001). The emotional impact on quality of life
showed a statistically signiﬁcant difference
(accompanied with a moderate effect size)
between NYHA I and II–III classiﬁed subjects.
The substantial difference between both esti-
mates of the magnitude of the difference between
NYHA I and II–III may be determined by the
dominant physical component of the NYHA clas-
siﬁcation. The correlations with conceptually
related emotional dimensions (scales) were,
while signiﬁcant, of moderate magnitude. The
cultural differences between the American and
Dutch society, in combination with semantic dif-
ferences in the translation of the items, are prob-
ably explanatory factors. ‘Making your going
places away from home difﬁcult’ and ‘making you
stay in a hospital’ are probably more associated
with the emotional impact of disturbing the rela-
tionship with signiﬁcant others than with physi-
cal inhibition in the Dutch translation. The
results of the current study indicate that the
application of the MLHF-Q will enable Dutch
researchers to assess health-related quality of life
in clinical trials in which clinically relevant
change will occur. 
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